1-6 of 6
Ahmad Naim, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Parameswaran Hari, MD MRCP, Haris Ali, MD, Yi-Bin Chen, MD, Salman Fazal, MD, Tara K. Gregory, MD, Sarah M. Anand, MD, Ahmad Naim, MD, Dilan Paranagama, PhD, Valkal Bhatt, PharmD, Amy Blithe, RD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-140541
Published: 2020
Journal Articles

Disease Progression, Hospital Readmissions, and Clinical Outcomes of Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Multicenter Chart Review

Jingbo Yu, PhD, Becky Hanna, Dilan Paranagama, PhD, Jackson Tang, Ahmad Naim, MD, John P Galvin, MDMS,MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 1994.
https://doi.org/10.1182/blood-2019-127492
Published: 2019
Journal Articles

Impact of Myeloproliferative Neoplasms on Patients' Employment Status and Work Productivity in the United States: Results from the Living with MPN Patient Survey

Jingbo Yu, MHA, PhD, Shreekant Parasuraman, BPharm, PhD, Dilan Paranagama, PhD, Ahmad Naim, MD, David Dubinski, MBA, Andrew Bai, MS, Ruben Mesa, MD FACP
Journal: Blood
Blood (2016) 128 (22): 4256.
https://doi.org/10.1182/blood.V128.22.4256.4256
Published: 2016
Journal Articles

Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study

Brady L. Stein, MD, Ahmad Naim, MD, Michael R. Grunwald, MD, Alison R. Moliterno, MD, Stephen T. Oh, MD PhD, Dilan Paranagama, PhD, Joseph A. Cordaro, PharmD, MBA, Hao Sun, MS, Shreekant Parasuraman, BPharm, PhD, Ralph V. Boccia, Ruben Mesa, MD FACP
Journal: Blood
Blood (2016) 128 (22): 1934.
https://doi.org/10.1182/blood.V128.22.1934.1934
Published: 2016
Journal Articles

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Ahmad Naim, MD, Smitha Svaraman, PhD, Jessy Gao, MA, Jason R. Gotlib, MD, Vikas Gupta, MD FRCP, FRCPath, Kim-Hien Dao, DO, PhD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1949.
https://doi.org/10.1182/blood.V128.22.1949.1949
Published: 2016
Journal Articles

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Srdan Verstovsek, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Jason R. Gotlib, MD, Ruben A. Mesa, MD, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francisco Cervantes, MD PhD, William Sun, PhD, Jessy Gao, MA, Touchuan Dong, Ahmad Naim, MD, Prashanth Gopalakrishna, MBBS, MRCS, Claire N. Harrison, DM, FRCP, FRCPath
Journal: Blood
Blood (2016) 128 (22): 3110.
https://doi.org/10.1182/blood.V128.22.3110.3110
Published: 2016